NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free FBRX Stock Alerts $0.71 -0.04 (-5.33%) (As of 12:44 PM ET) Add Compare Share Share Today's Range$0.71▼$0.7550-Day Range$0.62▼$0.7852-Week Range$0.38▼$1.11Volume6,253 shsAverage Volume30,428 shsMarket Capitalization$25.87 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Forte Biosciences alerts: Email Address Forte Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside287.3% Upside$2.75 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.82 out of 5 starsMedical Sector330th out of 905 stocksPharmaceutical Preparations Industry141st out of 422 stocks 3.3 Analyst's Opinion Consensus RatingForte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of Forte Biosciences have been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBRX. Previous Next 1.3 News and Social Media Coverage News SentimentForte Biosciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.MarketBeat FollowsOnly 2 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($0.46) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesMay 2, 2024 | americanbankingnews.comTraders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX)April 10, 2024 | benzinga.comForte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, PredictionsMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 8, 2024 | markets.businessinsider.comBuy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market PositionMarch 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…November 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXNovember 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSeptember 14, 2023 | finance.yahoo.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingSeptember 6, 2023 | finance.yahoo.comConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomAugust 25, 2023 | businesswire.comConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersAugust 25, 2023 | 247wallst.comCamac Fund Now Owns 4.3% of Forte BiosciencesAugust 14, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 3, 2023 | benzinga.comChief Financial Officer At This Health Care Company Buys $149K of StockAugust 1, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102July 4, 2023 | finance.yahoo.comThis Forte Biosciences Insider Increased Their Holding In The Last YearMay 24, 2023 | finance.yahoo.comWe're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn RateMay 19, 2023 | finance.yahoo.comForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesMay 15, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business UpdateApril 6, 2023 | msn.comUnusual Call Option Trade in Forte Biosciences (FBRX) Worth $2.50KMarch 31, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business UpdateJanuary 28, 2023 | seekingalpha.comFBRX Forte Biosciences, Inc.See More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/09/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside+266.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.27% Return on Assets-81.36% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.77Miscellaneous Outstanding Shares36,440,000Free Float32,605,000Market Cap$27.33 million OptionableOptionable Beta0.46 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $914.5kMr. Antony A. Riley CPA (Age 57)Chief Financial Officer Comp: $532kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsIterum TherapeuticsNASDAQ:ITRMBiora TherapeuticsNASDAQ:BIOROncternal TherapeuticsNASDAQ:ONCTLipocineNASDAQ:LPCNQilian International Holding GroupNASDAQ:QLIView All CompetitorsInsiders & InstitutionsCable Car Capital LLCBought 2,031,987 shares on 2/20/2024Ownership: 5.593%Paul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)Paul A WagnerBought 36,203 shares on 12/7/2023Total: $20,997.74 ($0.58/share)View All Insider TransactionsView All Institutional Transactions FBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Forte Biosciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FBRX shares. View FBRX analyst ratings or view top-rated stocks. What is Forte Biosciences' stock price target for 2024? 2 equities research analysts have issued 1 year price objectives for Forte Biosciences' stock. Their FBRX share price targets range from $2.75 to $2.75. On average, they anticipate the company's share price to reach $2.75 in the next year. This suggests a possible upside of 287.3% from the stock's current price. View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts. How have FBRX shares performed in 2024? Forte Biosciences' stock was trading at $0.8217 at the beginning of the year. Since then, FBRX shares have decreased by 13.6% and is now trading at $0.71. View the best growth stocks for 2024 here. Are investors shorting Forte Biosciences? Forte Biosciences saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 34,100 shares, a drop of 19.2% from the March 15th total of 42,200 shares. Based on an average trading volume of 34,300 shares, the short-interest ratio is currently 1.0 days. View Forte Biosciences' Short Interest. When is Forte Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBRX earnings forecast. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.04) earnings per share for the quarter. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN). How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBRX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe Exchange348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.